

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Bodo Kuklinski et al.

Serial No.: 10/511,882

Filed: October 19, 2004

For: USE OF A MARE'S MILK
CONCENTRATE DRIED ON A HIGHLY
DISPERSED, BIOLOGICALLY INERT
MATRIX

Group Art Unit: 1651

Examiner: Laura J Schuberg

Atty. Dkt. No.: SONN:057US

CERTIFICATE OF ELECTRONIC SUBMISSION

DATE OF SUBMISSION: October 5, 2006

INFORMATION DISCLOSURE STATEMENT

MS AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:


In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R. § 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

A fee as set forth in 37 C.F.R. § 1.17(p) in the amount of \$180.00 is enclosed. If an appropriate check has not been enclosed, or if it is insufficient, the Commissioner is authorized to deduct the appropriate fee from Fulbright & Jaworski Account No.: 50-1212/SONN:057US.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Travis Wohlers
Reg. No. 57,423
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: October 5, 2006

Form PTO-1449 (modified)		Atty. Docket No. SONN:057US	Serial No. 10/511,882
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Bodo Kukliński <i>et al.</i>	
		Filing Date: October 19, 2004	Group: 1651
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1	4,559,222	12/17/85	Ensore <i>et al.</i>	424	486	05/04/83
Exam. Init.	Ref. Des.	Document Number	Date	Country	Language		

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Campigli <i>et al.</i> , "Silicon dioxide as support for amorphous and metastable crystalline forms of indomethacin. Correlation between drug thermodynamic activity and percutaneous absorption in vitro," <i>Garmaco, Edizione Pratica</i> , 43:57-70, 1988.0
	C2	Database WPI Section Ch, Week 199322 Derwent Publications Ltd., London, GB; Class B04, AN 1993-180727.
	C3	Database WPI Section Ch, Week 200121 Derwent Publications Ltd., London, GB; Class D21, An 2001-203417.
	C4	Muller-Goymann "Neuere hilfstoffe," <i>Deutsche apotheker Zeitung</i> , 132:2306-2311, 1992 (English Abstract).
	C5	Ratz and Mattheus, "Effects of some topically applied drugs on the skin surface lipids," <i>Dermatologische Monatsschrift</i> 161:948-951, 1975 (English Abstract).

25695136.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP § 609. DRAW A LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)